These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8475356)

  • 1. Treatment of septic shock with antibodies to tumour necrosis factor.
    Cohen J; Exley AR
    Schweiz Med Wochenschr; 1993 Mar; 123(11):492-6. PubMed ID: 8475356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot clinical trial of an anti-TNF alpha monoclonal antibody for the treatment of septic shock.
    Boillot A; Capellier G; Racadot E; Wijdenes J; Herve P; Barale F
    Clin Intensive Care; 1995; 6(2):52-6. PubMed ID: 10150799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy of sepsis and septic shock].
    Ivanović D; Gjurasin M; Gasparović V; Radonić R; Kvarantan M; Merkler M
    Lijec Vjesn; 1995 Jun; 117 Suppl 2():8-11. PubMed ID: 8649167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody.
    Hinshaw LB; Emerson TE; Taylor FB; Chang AC; Duerr M; Peer GT; Flournoy DJ; White GL; Kosanke SD; Murray CK
    J Trauma; 1992 Oct; 33(4):568-73. PubMed ID: 1433404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome.
    Tracey KJ
    Circ Shock; 1991 Oct; 35(2):123-8. PubMed ID: 1777947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tumor necrosis factor in sepsis and acute lung injury.
    Simpson SQ; Casey LC
    Crit Care Clin; 1989 Jan; 5(1):27-47. PubMed ID: 2647225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current prospects for the treatment of clinical sepsis.
    Suffredini AF
    Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor: an updated review of its biology.
    Tracey KJ; Cerami A
    Crit Care Med; 1993 Oct; 21(10 Suppl):S415-22. PubMed ID: 8403979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity.
    Kojika M; Sato N; Yaegashi Y; Suzuki Y; Suzuki K; Nakae H; Endo S
    Ther Apher Dial; 2006 Feb; 10(1):12-8. PubMed ID: 16556131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of circulating tumor necrosis factor. Its role in septic shock treatment.
    Janbon B; Vuillez JP; Carpentier F; Barnoud D; André-Poyaud P; Barbe G; Guignier M
    Ann Med Interne (Paris); 1992; 143 Suppl 1():13-6. PubMed ID: 1300881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sepsis syndrome: progress and therapeutic perspectives].
    Schaller MD
    Schweiz Med Wochenschr; 1992 May; 122(20):768-75. PubMed ID: 1604283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological status of septic and trauma patients. I. High tumor necrosis factor alpha serum levels in septic and trauma patients are not responsible for increased mortality; a prognostic value of serum interleukin 6.
    Adamik B; Zimecki M; Właszczyk A; Kübler A
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):169-75. PubMed ID: 9597083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy which neutralises the effects of TNF alpha and IL-1 beta attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat.
    Ruetten H; Thiemermann C
    J Physiol Pharmacol; 1997 Dec; 48(4):605-21. PubMed ID: 9444610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous hemofiltration in pigs with hyperdynamic septic shock affects cardiac repolarization.
    Stengl M; Sykora R; Krouzecky A; Chvojka J; Novak I; Varnerova V; Kuncova J; Nalos L; Sviglerova J; Matejovic M
    Crit Care Med; 2008 Dec; 36(12):3198-204. PubMed ID: 18936693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokines and septic shock. New perspectives on its treatment].
    Zamora Madaria E
    An Med Interna; 1993 Dec; 10(12):573-5. PubMed ID: 8049320
    [No Abstract]   [Full Text] [Related]  

  • 19. Release of tumor necrosis factor alpha and its soluble receptor p55 in clinical septic syndrome.
    Modzelewski B
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):213-9. PubMed ID: 9597089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor in the pathogenesis of infectious diseases.
    Beutler B; Grau GE
    Crit Care Med; 1993 Oct; 21(10 Suppl):S423-35. PubMed ID: 8403980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.